Evidence map›Paper›PMID 34623326›Full record

ArticleThe Journal of clinical investigation2021

Concordance of immunological events between intrarectal and intravenous SHIVAD8-EO infection when assessed by Fiebig-equivalent staging.

Joana Dias, Giulia Fabozzi, Kylie March, Mangaiarkarasi Asokan, Cassandra G Almasri, Jonathan Fintzi, Wanwisa Promsote, Yoshiaki Nishimura, John-Paul Todd, Jeffrey D Lifson and 6 more

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in The Journal of clinical investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. An angel or a devil? Current view on the role of CD8Journal of translational medicine · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 3 countries.

Joana DiasImmunology Laboratory, Vaccine Research Center.
Giulia FabozziTissue Analysis Core, Vaccine Research Center.
Kylie MarchTissue Analysis Core, Vaccine Research Center.
Mangaiarkarasi AsokanVirology Laboratory, Vaccine Research Center.
Cassandra G AlmasriVirology Laboratory, Vaccine Research Center.
Jonathan FintziBiostatistics Research Branch.
Wanwisa PromsoteImmunology Laboratory, Vaccine Research Center.
Yoshiaki NishimuraLaboratory of Molecular Biology, and.
John-Paul ToddTranslational Research Program, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Jeffrey D LifsonAIDS and Cancer Virus Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, USA.
Malcolm A MartinLaboratory of Molecular Biology, and.
Lucio GamaImmunology Laboratory, Vaccine Research Center.
Constantinos PetrovasTissue Analysis Core, Vaccine Research Center.
Amarendra PeguVirology Laboratory, Vaccine Research Center.
John R MascolaVirology Laboratory, Vaccine Research Center.
Richard A KoupImmunology Laboratory, Vaccine Research Center.
Institut de Recherche Vaccinale · FRSwiss Vaccine Research Institute · CHCancer Research And Biostatistics · USLeidos (United States) · USNational Institute of Allergy and Infectious Diseases · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
CCR NIH HHS HHSN261200800001CNCI NIH HHS 75N91019D00024NCI NIH HHS HHSN261200800001E
6 · The paper itself

Abstract

Primary HIV-1 infection can be classified into six Fiebig stages based on virological and serological laboratory testing, whereas simian-HIV (SHIV) infection in nonhuman primates (NHPs) is defined in time post-infection, making it difficult to extrapolate NHP experiments to the clinics. We identified and extensively characterized the Fiebig-equivalent stages in NHPs challenged intrarectally or intravenously with SHIVAD8-EO. During the first month post-challenge, intrarectally challenged monkeys were up to 1 week delayed in progression through stages. However, regardless of the challenge route, stages I-II predominated before, and stages V-VI predominated after, peak viremia. Decrease in lymph node (LN) CD4+ T cell frequency and rise in CD8+ T cells occurred at stage V. LN virus-specific CD8+ T cell responses, dominated by degranulation and TNF, were first detected at stage V and increased at stage VI. A similar late elevation in follicular CXCR5+ CD8+ T cells occurred, consistent with higher plasma CXCL13 levels at these stages. LN SHIVAD8-EO RNA+ cells were present at stage II, but appeared to decline at stage VI when virions accumulated in follicles. Fiebig-equivalent staging of SHIVAD8-EO infection revealed concordance of immunological events between intrarectal and intravenous infection despite different infection progressions, and can inform comparisons of NHP studies with clinical data.

Indexed as

Administration, IntravenousAdministration, RectalAnimalsCD8-Positive T-LymphocytesDisease ProgressionFemaleHIV-1HIV InfectionsHumansMacaca mulattaMaleSimian Acquired Immunodeficiency SyndromeSimian Immunodeficiency VirusTime FactorsTranslational Research, BiomedicalViral LoadAdaptive immunityAIDS/HIVCellular immune responseImmunologyT cells

Identifiers

PMID34623326
PMCPMC8409578
OpenAlexW3196820422

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.